Join to View Full Profile
243 Charles StBoston, MA 02114
Phone+1 617-573-3367
Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts Eye and Ear/Harvard Medical SchoolResidency, Ophthalmology, 2001
Harvard Medical SchoolClass of 1997
Certifications & Licensure
MA State Medical License 2001 - 2026
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Start of enrollment: 2008 Jun 01
- Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD Start of enrollment: 2010 Aug 01
- Dexamethasone Implant for Retinal Detachment in Uveal Melanoma Start of enrollment: 2018 Apr 16
- Join now to see all
Publications & Presentations
PubMed
- Malignant Transformation of Ocular Melanocytoma to Uveal Melanoma: A Clinicopathologic Review of Three Novel Unsuspected Cases of a Likely Under-Recognized Phenomenon,...Fabliha A Mukit, Nicole E Terfloth, Ivana K Kim, Frances Wu, Anna M Stagner
American Journal of Ophthalmology. 2025-08-01 - Early Genetic Evolution of Driver Mutations in Uveal Melanoma.James J Dollar, Christina L Decatur, Ezekiel Weis, Amy C Schefler, Miguel A Materin
Medrxiv. 2025-06-12 - The Association between Gene Expression Profiling and Regression Rate of Posterior Uveal Melanoma following Proton Beam Irradiation.Disorn Suwajanakorn, Anne Marie Lane, Frances Wu, Evangelos S Gragoudas, Ivana K Kim
Ocular Oncology and Pathology. 2025-04-01
Journal Articles
- Survival Rates in Patients After Treatment for Metastasis from Uveal MelanomaIvana K Kim, Evangelos S Gragoudas, JAMA
Press Mentions
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 12th, 2024- Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 12th, 2024
- Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-Sar as a First-Line Treatment for Early-Stage Choroidal MelanomaSeptember 12th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
